Login Register Cart 0
Mini-Review Article

间充质干细胞疗法对COVID-19的可行性：迷你审查。

卷 20, 期 4, 2020

页: [285 - 288] 页: 4

弟呕挨: 10.2174/1566523220999200820172829

open access plus

conference banner
摘要

感染SARS-CoV-2的患者携带冠状病毒病2019（COVID-19），该疾病涉及多个系统和器官，其中最常见的并发症是急性呼吸窘迫综合征（ARDS），主要是由于细胞因子风暴或免疫功能失调。因此，有许多严重并发症，例如细胞因子风暴综合征（CSS），其病死率很高。目前既没有特定的抗SARS-CoV-2药物也没有疫苗。当前的治疗主要依靠通过患者的免疫功能自我恢复。间充质干细胞（MSCs）是一种多能组织干细胞，具有强大的抗炎和免疫调节功能，抑制细胞因子风暴。此外，间充质干细胞具有强大的修复组织损伤的能力，并能降低严重并发症（如急性肺损伤和ARDS）的风险，并有望降低这些患者的死亡率。目前已经完成了几种用MSC治疗COVID-19的临床研究，所有研究都报告了T细胞的恢复和临床安全性。在这里，我们讨论了临床前景，并总结了MSC治疗COVID-19的疗效和潜在机制。

关键词: 间充质干细胞，免疫，调节，修复，COVID-19，分泌组。

« Previous Next »
图形摘要

[1]
De Deyn MLZQ, Ng QX, Loke W, Yeo WS. A tale of two cities: A comparison of Hong Kong and Singapore’s early strategies for the Coronavirus Disease 2019 (COVID-19). J Infect 2020; 81(3): e51-2.
[http://dx.doi.org/10.1016/j.jinf.2020.06.058] [PMID: 32593657]
[2]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[3]
Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate forms of coronavirus disease 2019. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.02.16.20023903]
[4]
Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020; 95(6): E131-4.
[http://dx.doi.org/10.1002/ajh.25774] [PMID: 32129508]
[5]
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 55(5): 105955.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105955] [PMID: 32234468]
[6]
Golchin A, Farahany TZ. Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep 2019; 15(2): 166-75.
[http://dx.doi.org/10.1007/s12015-018-9866-1] [PMID: 30623359]
[7]
Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19) induced pneumonia. Aging Dis 2020; 11(2): 462-4.
[http://dx.doi.org/10.14336/AD.2020.0301] [PMID: 32257554]
[8]
Liu S, Peng D, Qiu H, Yang K, Fu Z, Zou L. Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Res Ther 2020; 11(1): 169.
[http://dx.doi.org/10.1186/s13287-020-01678-8] [PMID: 32366290]
[9]
Zumla A, Wang FS, Ippolito G, et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis 2020; 96: 431-9.
[http://dx.doi.org/10.1016/j.ijid.2020.05.040] [PMID: 32425638]
[10]
Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci 2015; 1351: 114-26.
[http://dx.doi.org/10.1111/nyas.12815] [PMID: 26152292]
[11]
Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal stromal cell secretome for severe covid-19 infections: premises for the therapeutic use. Cells 2020; 9(4): 924.
[http://dx.doi.org/10.3390/cells9040924] [PMID: 32283815]
[12]
Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells 2019; 8(8): 784.
[http://dx.doi.org/10.3390/cells8080784] [PMID: 31357692]
[13]
Rajarshi K, Chatterjee A, Ray S. Combating covid-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst) 2020; 26: e00467.
[http://dx.doi.org/10.1016/j.btre.2020.e00467] [PMID: 32420049]
[14]
Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med 2020; 9(1): 28-38.
[http://dx.doi.org/10.1002/sctm.19-0205] [PMID: 31647191]
[15]
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105(4): 1815-22.
[http://dx.doi.org/10.1182/blood-2004-04-1559] [PMID: 15494428]
[16]
Khare D, Or R, Resnick I, Barkatz C, Almogi-Hazan O, Avni B. Mesenchymal stromal cell-derived exosomes affect mrna expression and function of b-lymphocytes. Front Immunol 2018; 9: 3053.
[http://dx.doi.org/10.3389/fimmu.2018.03053] [PMID: 30622539]
[17]
Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med 2017; 196(10): 1275-86.
[http://dx.doi.org/10.1164/rccm.201701-0170OC] [PMID: 28598224]
[18]
Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014; 15(11): 1009-16.
[http://dx.doi.org/10.1038/ni.3002] [PMID: 25329189]
[19]
Yang Y, Hu S, Xu X, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Med Inflamm 2016; 2016: 2347938.
[http://dx.doi.org/10.1155/2016/2347938] [PMID: 27313398]
[20]
Deffune E, Prudenciatti A, Moroz A. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients. Med Hypotheses 2020; 14: 2109769.
[http://dx.doi.org/10.1016/j.mehy.2020.109769] [PMID: 32371362]
[21]
Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther 2016; 7(1): 125.
[http://dx.doi.org/10.1186/s13287-016-0363-7] [PMID: 27581859]
[22]
Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med 2017; 6(6): 1445-51.
[http://dx.doi.org/10.1002/sctm.17-0051] [PMID: 28452204]
[23]
Crivelli B, Chlapanidas T, Perteghella S, et al. Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J Control Release 2017; 262: 104-17.
[PMID: 28736264]
[24]
Ji F, Li L, Li Z, Jin Y, Liu W. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem Cells Transl Med 2020; 9(7): 813-4.
[http://dx.doi.org/10.1002/sctm.20-0083] [PMID: 32320535]
[25]
Di Rocco G, Baldari S, Toietta G. Towards therapeutic delivery of extracellular vesicles: strategies for in vivo tracking and bio distribution analysis. Stem Cells Int 2016; 2016: 5029619.
[http://dx.doi.org/10.1155/2016/5029619] [PMID: 27994623]
[26]
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 2020; 29(12): 747-54.
[http://dx.doi.org/10.1089/scd.2020.0080] [PMID: 32380908]
[27]
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia. Aging Dis 2020; 11(2): 216-28.
[http://dx.doi.org/10.14336/AD.2020.0228] [PMID: 32257537]
[28]
Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov 2020; 51: 00019.
[http://dx.doi.org/10.1016/j.medidd.2020.100019] [PMID: 32296777]
[29]
Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for covid-19: present or future. Stem Cell Rev Rep 2020; 16(3): 427-33.
[http://dx.doi.org/10.1007/s12015-020-09973-w] [PMID: 32281052]

Rights & Permissions Print Cite
Article Metrics
33
© 2024 Bentham Science Publishers | Privacy Policy